Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOVALDI vs ANEXSIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, which is essential for viral replication. It is converted to the active triphosphate form (GS-461203) that competes with natural nucleotides and causes chain termination upon incorporation into viral RNA.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Treatment of chronic hepatitis C virus (HCV) infection as a component of a combination antiviral regimen (FDA approved),Off-label: Treatment of HCV in patients with hepatocellular carcinoma awaiting liver transplantation
Relief of moderate to moderately severe pain
400 mg orally once daily with or without food.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
Terminal half-life of sofosbuvir is approximately 0.4-0.5 hours; the predominant circulating metabolite GS-331007 has a terminal half-life of 27 hours. This long half-life supports once-daily dosing.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Sofosbuvir is a prodrug that undergoes extensive hepatic metabolism to form the active triphosphate. It is metabolized by cathepsin A (Cat A) and carboxylesterase 1 (CES1), followed by phosphorylation by nucleoside kinases. The inactive metabolite GS-331007 is eliminated renally.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Primarily fecal (77% of absorbed dose as metabolites, 3.5% as unchanged drug) with minor renal elimination (3.5% total, mainly metabolites). Biliary excretion contributes to fecal elimination.
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
Sofosbuvir is 61-65% bound to human plasma proteins; the metabolite GS-331007 has minimal protein binding (<1%).
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
Sofosbuvir: approximately 0.25 L/kg (based on 80 kg individual, Vd ~20 L), suggesting limited extravascular distribution. GS-331007: Vd is not clinically relevant as it is inactive.
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
Oral bioavailability of sofosbuvir is not precisely determined but is adequate for therapeutic effect; absorption is enhanced by food (high-fat meal increases AUC by ~1.8-fold).
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m2) or end-stage renal disease requiring hemodialysis, no prospective data; may use with caution but insufficient data to recommend dose adjustment.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for use in patients with severe hepatic impairment (Child-Pugh C) due to significantly increased exposure and potential toxicity; contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Approved for patients aged 3 years and older: weight <17 kg: 150 mg orally once daily; weight 17 to <35 kg: 200 mg orally once daily; weight ≥35 kg: 400 mg orally once daily; administer with food.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
No specific dose adjustment required for elderly patients; dosing based on hepatic and renal function with consideration of age-related decline in renal function. Monitor for adverse events as elderly may have higher risk of comorbidities and concomitant medications.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
NOT APPROVED BY FDA FOR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION. WAIT, SOVALDI IS APPROVED. CORRECTION: No black box warning for Sovaldi (sofosbuvir) as a single agent. However, when used in combination with other antivirals, there is a risk of hepatitis B virus (HBV) reactivation. The FDA has issued a boxed warning regarding HBV reactivation for direct-acting antivirals, including sofosbuvir-containing regimens.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
Risk of hepatitis B virus reactivation in patients coinfected with HBV and HCV, which can lead to fulminant hepatitis and death.,Symptomatic bradycardia when used with amiodarone, especially in patients also taking beta-blockers or with underlying cardiac comorbidities.,Reduced efficacy in patients with genotype 3 HCV infection when used without ribavirin.,Use with caution in patients with severe renal impairment (e GFR <30 m L/min) or end-stage renal disease due to increased exposure of the metabolite GS-331007.
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
Hypersensitivity to sofosbuvir or any component of the formulation,Coadministration with potent P-glycoprotein (P-gp) inducers (e.g., rifampin, St. John's wort) which may significantly reduce sofosbuvir efficacy
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
No significant food interactions. May be taken with or without food. Grapefruit or other fruit juices have no known clinically relevant interaction with sofosbuvir.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
Sovaldi (sofosbuvir) is classified as FDA Pregnancy Category B. Animal studies have shown no evidence of teratogenicity at exposures up to 10 times the human therapeutic dose. However, human data are limited. In animal reproduction studies, no fetal harm was observed in rats and rabbits at exposures 10 and 5 times the human exposure, respectively. No dose-limiting maternal or fetal toxicity was noted in rats or rabbits. The risk of teratogenicity in humans is considered low, but because of limited human data, use during pregnancy should only be if clearly needed. Ribavirin, which is commonly used in combination with sofosbuvir for chronic hepatitis C, is contraindicated in pregnancy due to its known teratogenic and embryocidal effects (Pregnancy Category X). Therefore, concomitant use of ribavirin imposes significant fetal risk, especially during the first trimester.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
It is not known whether sofosbuvir or its metabolites are excreted in human breast milk. In lactating rats, sofosbuvir was detected in milk at concentrations similar to maternal plasma. The M/P ratio in rats was approximately 1.0. The pharmacokinetics in nursing infants have not been evaluated. Because of the potential for adverse reactions in breastfed infants, and because ribavirin (if coadministered) is contraindicated during lactation, breastfeeding is not recommended during treatment with Sovaldi. The CDC recommends that women with chronic HCV can breastfeed, as HCV is not transmitted through breast milk; however, the safety of sofosbuvir during lactation has not been established.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
No specific dosing adjustments for sofosbuvir are recommended during pregnancy based on pharmacokinetic changes. In animal studies, pharmacokinetics were not significantly altered in pregnant vs non-pregnant animals. However, physiological changes in pregnancy (e.g., increased plasma volume, altered hepatic metabolism) may affect drug disposition, but no clinical data are available to support dose adjustment. If used with ribavirin, ribavirin dose should be based on body weight (1000 mg/day if <75 kg, 1200 mg/day if ≥75 kg, divided twice daily) and adjusted for hematologic toxicity. For severe renal impairment (e GFR <30 m L/min/1.73 m²), sofosbuvir is not recommended due to increased exposure of its metabolite. In all cases, the combination of sofosbuvir with ribavirin is not recommended during pregnancy due to ribavirin's teratogenicity.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
Sovaldi (sofosbuvir) is a pangenotypic NS5B polymerase inhibitor used in combination with other direct-acting antivirals for chronic hepatitis C. Monitor for bradycardia when coadministered with amiodarone; avoid concurrent use if possible. Renal impairment (e GFR <30 m L/min) is a contraindication due to accumulation of the sofosbuvir metabolite GS-331007. All-oral regimens achieve >95% sustained virologic response. Hepatitis B reactivation risk requires screening and monitoring.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
Take this medication exactly as prescribed, usually once daily with or without food.,Do not stop taking this medication without consulting your doctor, even if you feel well.,Use effective contraception during treatment and for 30 days after finishing, as ribavirin-containing regimens can cause birth defects.,Report any signs of serious side effects like slow heartbeat (dizziness, fainting) or allergic reactions.,Avoid drinking alcohol as it can worsen liver disease and reduce treatment effectiveness.,Inform your doctor about all medications, including over-the-counter drugs and supplements, to avoid interactions.,You will need regular blood tests to monitor liver function, viral load, and side effects.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOVALDI vs ANEXSIA, answered by our medical review team.
SOVALDI is a Direct-acting antiviral that works by Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, which is essential for viral replication. It is converted to the active triphosphate form (GS-461203) that competes with natural nucleotides and causes chain termination upon incorporation into viral RNA.. ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOVALDI and ANEXSIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOVALDI is: 400 mg orally once daily with or without food.. The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOVALDI and ANEXSIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOVALDI is classified as Category C. Sovaldi (sofosbuvir) is classified as FDA Pregnancy Category B. Animal studies have shown no evidence of teratogenicity at exposures up to 10 times the human therapeutic dose. Howe. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.